Home › Inflammatory Bowel Disease › Pennsylvania › Pittsburgh
Inflammatory Bowel Disease clinical trials in Pittsburgh, PA
5 studies for Inflammatory Bowel Disease are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease
RecruitingPhase 4
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
RecruitingObservational study
- University of Pittsburgh Medical Center, Children's Hospital, Pittsburgh
Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
RecruitingObservational study
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
RecruitingPhase 2
- UPMC Children's Hospital of Pittsburgh, Pittsburgh
Inflammatory Bowel Disease trials in other cities
- New York City, NY18 studies
- Boston, MA15 studies
- Seattle, WA9 studies
- Miami, FL9 studies
- Houston, TX8 studies
- Orlando, FL8 studies
- Atlanta, GA8 studies
- Durham, NC8 studies
- Washington, DC7 studies
- St. Louis, MO7 studies
- Philadelphia, PA7 studies
- Cincinnati, OH7 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Lung Cancer23 studies
- Prostate Cancer23 studies
- Stroke22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.